Ocaña A - Search Results

1

Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis.

Burgos M, Cavero-Redondo I, Álvarez-Bueno C, Galán-Moya EM, Pandiella A, Amir E, Ocaña A. Burgos M, et al. Among authors: ocana a. Ther Adv Med Oncol. 2022 Jan 19;14:17588359211072621. doi: 10.1177/17588359211072621. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35082925 Free PMC article.

2

Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.

Ocaña A, Cruz JJ, Pandiella A. Ocaña A, et al. Am J Clin Oncol. 2006 Feb;29(1):90-5. doi: 10.1097/01.coc.0000190274.00570.0a. Am J Clin Oncol. 2006. PMID: 16462510 Review.

3

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.

Cruz JJ, Ocaña A, Del Barco E, Pandiella A. Cruz JJ, et al. Among authors: ocana a. Ann Oncol. 2007 Mar;18(3):421-30. doi: 10.1093/annonc/mdl175. Epub 2006 Jul 27. Ann Oncol. 2007. PMID: 16873430 Free article. Review.

4

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.

de Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A. de Alava E, et al. Among authors: ocana a. J Clin Oncol. 2007 Jul 1;25(19):2656-63. doi: 10.1200/JCO.2006.08.6850. J Clin Oncol. 2007. PMID: 17602072

5

An update into the pathophysiological role of HER2 in cancer: therapeutic implications.

Ocaña A, Pandiella A. Ocaña A, et al. Clin Transl Oncol. 2007 Sep;9(9):543-4. doi: 10.1007/s12094-007-0100-x. Clin Transl Oncol. 2007. PMID: 17921099 No abstract available.

6

Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.

Ocaña A, Pandiella A. Ocaña A, et al. Clin Cancer Res. 2008 Feb 15;14(4):961-70. doi: 10.1158/1078-0432.CCR-07-1630. Clin Cancer Res. 2008. PMID: 18281527 Review.

7

Neuregulins and cancer.

Montero JC, Rodríguez-Barrueco R, Ocaña A, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A. Montero JC, et al. Among authors: ocana a. Clin Cancer Res. 2008 Jun 1;14(11):3237-41. doi: 10.1158/1078-0432.CCR-07-5133. Clin Cancer Res. 2008. PMID: 18519747 Review.

8

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, Pandiella A. Esparís-Ogando A, et al. Among authors: ocana a. Ann Oncol. 2008 Nov;19(11):1860-9. doi: 10.1093/annonc/mdn406. Epub 2008 Jul 17. Ann Oncol. 2008. PMID: 18641009 Free article.

9

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.

Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparís-Ogando A. Montero JC, et al. Among authors: ocana a. PLoS One. 2009;4(5):e5565. doi: 10.1371/journal.pone.0005565. Epub 2009 May 15. PLoS One. 2009. PMID: 19440538 Free PMC article.

10

Novel tyrosine kinase inhibitors in the treatment of cancer.

Ocana A, Serrano R, Calero R, Pandiella A. Ocana A, et al. Curr Drug Targets. 2009 Jun;10(6):575-6. doi: 10.2174/138945009788488378. Curr Drug Targets. 2009. PMID: 19519359 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

276 results

Search Page